Spot on OP
Remestemcel-L for GVHD:
Mesoblast’s product development strategy
1. Target pediatric patients with steroid refractory-aGVHD first (upto 17 yrs of age)
2. Seek label extension for high-risk adult patients with steroid refractory-aGVHD
3. Lifecycle potential in chronic GVHD (cGVHD)
Ann: DMC Completes Final Review of Phase 3 Heart Failure Trial, page-72
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.50 |
Change
0.005(0.34%) |
Mkt cap ! $1.701B | |||
| Open | High | Low | Value | Volume |
| $1.57 | $1.58 | $1.49 | $5.789M | 3.771M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 5214 | $1.50 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.50 | 20000 | 1 |
View Market Depth
| Last trade - 10.43am 07/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |